PathWays Case Study: Sept. 19

By Rene Revier • September 19, 2017

Share this:

Following three years of disease-free status, a patient presented with a recurrent monoclonal IgGK immunoglobulin during a routine follow-up evaluation (PEL 1). Therapy was reinstated and consisted of daratumumab, lenalidomide, and dexamethasone. Despite clinical improvement, two detectable monoclonal proteins of IgGΚ isotype were found on follow-up a month later (PEL 2, and IFE). The primary clone had declined in concentration from 0.8 g/dL to 0.4 g/dL while the second (new) clone could not be quantitated.

Lusia Sepiashvili, Ph.D.
Resident, Clinical Biochemistry
Mayo Clinic

Maria Willrich, Ph.D.
Consultant, Clinical Biochemistry
Mayo Clinic
Assistant Professor of Laboratory Medicine and Pathology
Mayo Clinic College of Medicine and Sciences

Rene Revier

Rene Revier is an Editorial Assistant at Mayo Medical Laboratories. She supports Mayo Clinic PathWays and other corporate communications activities.